CervoMed Inc.
No enriched coverage for $CRVO in the last 7 days.
No SEC Form 4 filings for $CRVO in the last 30 days.
See all $CRVO insider activity →CervoMed Inc. (CRVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation und
CervoMed Inc. (NASDAQ: CRVO) reported at AAIC 2026 new Phase 2b analyses for neflamapimod in dementia with Lewy bodies. The company said results support selecting 50 mg TID for a planned Phase 3, citing effects on CDR-SB, plasma pTau181 exposure, and MRI basal forebrain atrophy/connectivity. It also reported Phase 2 data for 80 mg BID meeting safety and PK objectives.
CervoMed (NASDAQ: CRVO) said it completed enrollment in a Phase 2a trial of oral p38a inhibitor neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study enrolled 25 patients and includes 24 weeks of dosing plus a 12-week randomized placebo-controlled extension. Interim biomarker data are slated for CTAD in Nov 2026, with first biomarker and clinical data expected Q4 2026 and Q1 2027.
Recent CRVO coverage spans corporate actions, financial news and technology.
The filing adds clinical and regulatory-development catalysts plus a financing runway update, but the key near-term variable is securing a Phase 3 partner.
AAIC conference data strengthens the Phase 3 dosing rationale (50 mg TID) and reframes the prior Phase 2b miss as exposure and AD co-pathology related.
Enrollment completion de-risks trial execution and sets a clear catalyst path to interim biomarker presentation and later clinical data.
The filing discloses warrant/financing mechanics that can affect dilution expectations and near-term trading risk for CRVO.
The filing signals insider accumulation, but it is an indirect holding and not tied to a 10b5-1 plan, limiting immediate fundamental read-through.
alphai scores every news story that mentions CRVO with an AI model for sentiment and relevance, and aggregates insider trades from CervoMed Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CervoMed Inc. (CRVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation und
6 min readCervoMed Inc. (NASDAQ: CRVO) reported at AAIC 2026 new Phase 2b analyses for neflamapimod in dementia with Lewy bodies. The company said results support selecting 50 mg TID for a planned Phase 3, citing effects on CDR-SB, plasma pTau181 exposure, and MRI basal forebrain atrophy/connectivity. It also reported Phase 2 data for 80 mg BID meeting safety and PK objectives.
6 min readCervoMed (NASDAQ: CRVO) said it completed enrollment in a Phase 2a trial of oral p38a inhibitor neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study enrolled 25 patients and includes 24 weeks of dosing plus a 12-week randomized placebo-controlled extension. Interim biomarker data are slated for CTAD in Nov 2026, with first biomarker and clinical data expected Q4 2026 and Q1 2027.
2 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ex_978640.htm EXHIBIT 4.1 ex_978640.htm Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FR
3 min readBOGER JOSHUA S purchased 955,414 indirectly-held shares of CervoMed Inc. (CRVO) at $3.14 ($3.00M total) on 2026-06-11.
2 min readCervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, extending its cash runway into Q2 2027, according to the company. Funds will support a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies. Over six months, it expects Phase 2a 24-week biomarker/clinical data and to start EXPERTS-ALS Phase 2a.
6 min readCervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, with net proceeds extending its cash runway into Q2 2027. The company plans to prioritize securing a strategic partner to advance neflamapimod to Phase 3 for dementia with Lewy bodies. It also cited upcoming Phase 2a milestones in nfvPPA and ALS.
6 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex_974988.htm EXHIBIT 10.1 ex_974988.htm Exhibit 10.1 Execution Version CERVOMED INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “ Agreement ”) is made as of June 9, 2026 (the “ Effective Date ”), by and between CervoMed Inc. , a Delaware corp
3 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crvo20260609_8k.htm false 0001053691 0001053691 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 8, 2026 Date of Report (Date of earlie
2 min readMarketBeat.com compares medical firms CervoMed (NASDAQ:CRVO) and Pathfinder Cell Therapy (OTCMKTS:PFND). It cites institutional ownership of 25.2% for CervoMed versus 15.1% insiders for Pathfinder, and notes CervoMed has a consensus price target of $22.60. The article says CervoMed outperforms Pathfinder on 6 of 9 factors, including analyst ratings and possible upside.
4 min read
